Yong Xiang Wang
Corporate Officer/Principal at SIRNAOMICS LTD.
Net worth: 3 425 $ as of 2024-05-30
Profile
Yong Xiang Wang is currently the Chief Production Officer at Sirnaomics Ltd.
He previously worked as the Director-Vaccine Production at NewLink Genetics Corp.
from 2014 to 2016.
Prior to that, he was the Deputy Director-Engineering at Aeras Global TB Vaccine Foundation from 2007 to 2011.
He also served as the Technology Director at Charter Medical Ltd.
in 2005 and 2006.
In addition, he worked as a Technology Consultant-Parexel International at Ben Venue Laboratories, Inc. from 2011 to 2012 and as the Vice President-Technical Operations at WuXi AppTec Co., Ltd.
from 2012 to 2014.
He was also the Deputy General Manager at Shanghai Furen Medicine R&D Co., Ltd.
from 2016 to 2018.
Dr. Wang received his undergraduate degree from the University of Science & Technology of China in 1976.
He then obtained a graduate degree from Tokyo Institute of Technology in 1983 and a doctorate degree from Aalto University School of Science & Technology in 1995.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SIRNAOMICS LTD.
0.00% | 2024-06-19 | 3,601 ( 0.00% ) | 3 425 $ | 2024-05-30 |
Yong Xiang Wang active positions
| Companies | Position | Start |
|---|---|---|
| SIRNAOMICS LTD. | Corporate Officer/Principal | 2021-12-14 |
Former positions of Yong Xiang Wang
| Companies | Position | End |
|---|---|---|
| Shanghai Furen Medicine R&D Co., Ltd. | Corporate Officer/Principal | 2018-05-31 |
| LUMOS PHARMA, INC. | Corporate Officer/Principal | 2016-05-31 |
| WUXI APPTEC CO., LTD. | Corporate Officer/Principal | 2014-01-31 |
Ben Venue Laboratories, Inc.
 Ben Venue Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Ben Venue Laboratories, Inc. develops and manufactures sterile liquid products. Its products include Lyophilized Dosages, Small Molecule Pharmaceuticals, Cytotoxics, and Potent Compounds. The company was founded by R. Templeton Smith in 1938 and is headquartered in Bedford, OH. | Corporate Officer/Principal | 2012-09-30 |
Aeras Global TB Vaccine Foundation
 Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Corporate Officer/Principal | 2011-09-30 |
Training of Yong Xiang Wang
| University of Science & Technology of China | Undergraduate Degree |
| Tokyo Institute of Technology | Graduate Degree |
| Aalto University School of Science & Technology | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| WUXI APPTEC CO., LTD. | Health Technology |
| SIRNAOMICS LTD. | Health Technology |
| Private companies | 5 |
|---|---|
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
Aeras Global TB Vaccine Foundation
Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Commercial Services |
Ben Venue Laboratories, Inc.
Ben Venue Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Ben Venue Laboratories, Inc. develops and manufactures sterile liquid products. Its products include Lyophilized Dosages, Small Molecule Pharmaceuticals, Cytotoxics, and Potent Compounds. The company was founded by R. Templeton Smith in 1938 and is headquartered in Bedford, OH. | Health Technology |
| Shanghai Furen Medicine R&D Co., Ltd. | |
Charter Medical Ltd.
 Charter Medical Ltd. BiotechnologyHealth Technology Charter Medical has an established history of providing specialty products to the blood transfusion and cell therapies and single-use bioprocessing containers to the biotechnology and pharmaceutical markets. Charter Medical was formed in 1998, a privately held medical device manufacturer of disposable blood transfusion and intravenous products located in Lakewood, NJ. Charter Medical continued production of the existing CharterMed medical devices and expanded the product line to include bioprocessing bags. Manufacturing began at the Winston-Salem headquarters in 1998 in one ISO Class 8 cleanroom. In 2001, Charter Medical commissioned a second cleanroom at the 71,000 square foot site to expand the medical device and bioprocessing bag manufacturing capabilities. Through a second expansion in 2009, Charter Medical now houses 15,000 square feet of clean room space to support the ever growing demand for disposable products. | Health Technology |
- Stock Market
- Insiders
- Yong Xiang Wang
